Vivani Medical (VANI) investor relations material

Strategic partnerships and industry positioning

• Announced a new agreement with Novo Nordisk to evaluate the semaglutide implant, marking the first big pharma interest in this modality for GLP-1s.

• Positioned as the only active developer of a GLP-1 implant solution, offering unique differentiation from injectables and gene editing approaches.

• Platform technology aims to address both human and veterinary markets, with ongoing efforts to expand applications to newer incretin molecules and animal health.

Product development and clinical milestones

• Preparing to initiate the first dosing of the SLIM-1 clinical trial in August, following recent regulatory approval.

• The trial will start with a low dose matching the Wegovy titration sequence, assessing safety, tolerability, pharmacokinetics, and weight loss.

• Plans to progress to a dose-ranging study comparing three implant doses, placebo, and continued Wegovy treatment over six months.

• Preclinical data demonstrates the implant's ability to provide steady drug release for up to a year, supporting real-world adherence and efficacy.

Market opportunity and technology advantages

• GLP-1 implant offers infrequent administration (once or twice a year), addressing adherence and convenience gaps in obesity treatment.

• Implant can be removed at any time, providing flexibility and peace of mind compared to long-acting injectables.

• Technology aims to mitigate rapid weight rebound seen with discontinuation of current treatments by maintaining steady blood concentrations.

• Cash runway extends into the second half of 2027, supporting ongoing development and expansion.